Latest news with #AnkurDhingra
Yahoo
28-05-2025
- Business
- Yahoo
Stifel Affirms Buy Rating on Illumina (ILMN) Stock
Analysts at Stifel are bullish about Illumina, Inc.'s (NASDAQ:ILMN) prospects despite the stock capitulating 36% year to date. On May 28, the analysts reiterated a Buy rating on the stock and a $135 price target. The firm's confidence stems from recent investor meetings with Illumina's CFO Ankur Dhingra and Interim Head of Investor Relations Brian Blanchett, offering valuable insights into the company's performance and future outlook, especially regarding consumables beyond China. A biopharmaceutical research laboratory filled with scientists, illuminated by the glow of their equipment. Even though academic spending slowed in Q1, sequencing activity remains strong, and the clinical outlook looks positive. Illumina has a 68.6% gross margin and $4.3 billion in annual revenue. While Stifel analysts see some risk in expecting the same 30%+ growth for the rest of the year, management remains confident in its 2025 forecasts. Illumina's high-throughput (HT) consumables growth framework remains on track, with new product launches positioned as key drivers of future success. Stifel analysts caution that a complete loss of China revenue could lead to little or no growth in 2026, yet they see it as a potentially beneficial reset for the company's profit and loss statement, which could strengthen the stock's long-term outlook. Illumina is a life science company that develops and manufactures tools and systems for genomics research. It offers a range of products and services, including sequencing platforms and microarrays that enable clinicians to analyze genetic information and make discoveries. While we acknowledge the potential of Illumina, Inc. (NASDAQ:ILMN) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ILMN and that has 100x upside potential, check out our report about the cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28-05-2025
- Business
- Yahoo
Stifel Affirms Buy Rating on Illumina (ILMN) Stock
Analysts at Stifel are bullish about Illumina, Inc.'s (NASDAQ:ILMN) prospects despite the stock capitulating 36% year to date. On May 28, the analysts reiterated a Buy rating on the stock and a $135 price target. The firm's confidence stems from recent investor meetings with Illumina's CFO Ankur Dhingra and Interim Head of Investor Relations Brian Blanchett, offering valuable insights into the company's performance and future outlook, especially regarding consumables beyond China. A biopharmaceutical research laboratory filled with scientists, illuminated by the glow of their equipment. Even though academic spending slowed in Q1, sequencing activity remains strong, and the clinical outlook looks positive. Illumina has a 68.6% gross margin and $4.3 billion in annual revenue. While Stifel analysts see some risk in expecting the same 30%+ growth for the rest of the year, management remains confident in its 2025 forecasts. Illumina's high-throughput (HT) consumables growth framework remains on track, with new product launches positioned as key drivers of future success. Stifel analysts caution that a complete loss of China revenue could lead to little or no growth in 2026, yet they see it as a potentially beneficial reset for the company's profit and loss statement, which could strengthen the stock's long-term outlook. Illumina is a life science company that develops and manufactures tools and systems for genomics research. It offers a range of products and services, including sequencing platforms and microarrays that enable clinicians to analyze genetic information and make discoveries. While we acknowledge the potential of Illumina, Inc. (NASDAQ:ILMN) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ILMN and that has 100x upside potential, check out our report about the cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None.
Cision Canada
13-05-2025
- Business
- Cision Canada
ProHance Named a Major Contender in Everest Group's 2025 People Analytics Platforms PEAK Matrix® Assessment
FRISCO, Texas, May 13, 2025 /CNW/ -- ProHance, a new-age leader in workplace analytics and operations enablement platform, has been named a Major Contender in the Everest Group People Analytics Platforms PEAK Matrix ® Assessment 2025. The study evaluated 23 distinct analytics platforms and placed ProHance at the forefront of the North American Enterprise and SMB landscape; and highlighted the critical role it plays in helping organizations drive productivity, optimize workforce performance and make data-informed decisions. The Everest Group PEAK Matrix ® is a renowned benchmark that evaluates technology providers based on market impact, vision and capability. ProHance's inclusion is based on its strong customer traction, measurable ROI, and ability to scale enterprise-wide across industries. "With U.S. companies increasingly navigating hybrid and distributed workforce challenges, ProHance stands out for delivering real-time visibility into work patterns, operational efficiency, and employee engagement —empowering business and HR leaders to act decisively in dynamic environments. We are happy to earn the Major Contender status in Everest Group's distinguished People Analytics Platforms PEAK Matrix ® Assessment," commented Ankur Dhingra, CEO, ProHance. "ProHance's recognition as a Major Contender in Everest Group's People Analytics Platforms PEAK Matrix ® Assessment 2025 is driven by its ability to offer real-time insights into workforce productivity with a robust set of inputs captured from work-level activity. The work-output module enables a normalized view of output across diverse worker categories, enabling a meaningful enterprise-wide comparison. In addition to helping improve productivity, it also focuses on mitigating risk by offering an AI-powered Retention Risk Index to support attrition management, positioning ProHance as a robust platform for catering to the needs of enterprise workforce analytics," said Sharath Hari N, Vice President at Everest Group. Enterprise clients across North America validate this strategic value. "ProHance's placement on the PEAK Matrix ® is a true reflection of our experience as a client. Among the many platforms we assessed, ProHance stood out as the most comprehensive solution — providing real-time, enterprise-wide visibility, actionable insights, and seamless operational enablement. It has helped us drive productivity, optimize resource utilization, improve workforce efficiency, and strengthen governance," says Martin Edgerton, Head of Global Service Delivery at JLL.
Associated Press
20-03-2025
- Business
- Associated Press
ProHance to Lead Key Discussions at Shared Services & Outsourcing Week (SSOW) 2025 in Orlando
ProHance leaders to share insights on GBS, shared services versatility & talent transformation at SSOW 2025 Orlando with workshops, panels & expert discussions. ORLANDO, FL, UNITED STATES, March 20, 2025 / / -- ProHance, a new-age workplace analytics and operations enablement platform, is set to take center stage at the Shared Services & Outsourcing Week (SSOW) 2025 in Orlando. With a strong presence at the event, ProHance will deliver three impactful sessions featuring its leadership alongside industry experts. These sessions will offer strategic insights into building agile shared services models, leveraging empirical data for GBS transformation, and reimagining talent management in the digital era. Featured Sessions Panel Discussion: Transforming Talent Management for the Digital Future Date: March 24, 2025 Time: 2:00 PM Panelist: Khiv Singh, Senior Vice President & Head of Americas, ProHance Additional Panelists: Sue Dempsey, SVP, Acrisure Business Services, Acrisure Jack Deem, Assistant Controller, Con Edison Jim Thomsen, VP of Customer Care, Showdown Displays Mike Kresge, VP of Controller Shared Services, Leidos As organizations navigate rapid digital transformation, effective talent management is crucial to sustaining competitive advantage. This panel will explore best practices for attracting, developing, and retaining a future-ready workforce equipped with digital expertise and problem-solving capabilities. Key discussion points include: - Identifying critical skills required for future-proof teams - Balancing technical expertise with creativity to enhance productivity - Implementing upskilling and engagement strategies to drive talent retention - Aligning corporate culture with workforce transformation for long-term success Workshop: Building Shared Services Versatility – Balancing Depth and Breadth in a Fast-Paced Environment Date: March 25, 2025 Time: 9:00 AM Speakers: Ankur Dhingra, CEO, ProHance Fabiano Lopes, VP, Cardinal Health This workshop will provide an in-depth exploration of strategies to enhance the agility of shared services operations by balancing specialization with flexibility. As businesses evolve, organizations must adopt a model that seamlessly integrates depth and breadth to maximize efficiency and adaptability. Key takeaways will include: - Building operational resilience through a balanced skills and service model - Scaling shared services functions while maintaining efficiency and agility - Leveraging advanced technology and workforce analytics for optimal service delivery Track Session: The Hidden Catalyst in GBS Transformation – Trustworthy, Empirical Data Date: March 26, 2025 Time: 3:00 PM Speakers: Ankur Dhingra, CEO, ProHance Fabiano Lopes, VP, Cardinal Health Data-driven decision-making is a cornerstone of modern GBS transformation. This session will highlight how empirical data fosters trust, enhances operational efficiency, and accelerates business transformation. Attendees will gain insights into: - The role of real-time analytics and performance data in driving transformation - The importance of transparency and data integrity in building stakeholder confidence - Case studies demonstrating the tangible impact of data-driven GBS strategies About ProHance ProHance empowers organizations with a comprehensive suite of tools and capabilities designed to elevate productivity, enforce compliance, optimize costs, enhance customer satisfaction, enable data-driven decision-making, and seamlessly adapt to evolving business needs. Currently deployed by over 400,000+ users across 25 countries, ProHance provides cutting-edge solutions that help businesses achieve strategic objectives and operational excellence. For more information, visit X LinkedIn Instagram YouTube Other Legal Disclaimer:
Yahoo
10-03-2025
- Business
- Yahoo
Illumina lowers outlook due to China sales ban, to cut $100 million in costs
(Reuters) -Illumina on Monday lowered its annual forecast and said it plans to cut $100 million in spending after China announced a ban on imports of its genetic sequencing instruments. The company said it now expects 2025 adjusted profit of about $4.50 per share, compared to its previous expectation of $4.50 to $4.65 per share. The company added that the cost savings would mitigate the impact of a potential reduction in revenue and related operating income from the company's Greater China business. Shares of the company were up 3.5% at $89 in extended trading. "Our new fiscal 2025 guidance provides for limited further earnings contribution from China, and assumes a continuation of the macro trends we see today," said CFO Ankur Dhingra. China announced a ban on imports of genetic sequencers from Illumina that took effect from March 4, just minutes after U.S. President Donald Trump's additional 10% tariff on Chinese goods took effect. Gene sequencers help determine the sequence of DNA or RNA, allowing scientists to study genetic variations associated with diseases and diagnose rare genetic conditions. China accounts for about 7% of Illumina's sales. Its revenue from the Greater China region was $308 million in 2024. The company said on Monday that it respects the Chinese commerce ministry's decision and said it will continue to comply with all applicable laws and regulations wherever the company operates.
